Coagadex (Factor X) utilization and coverage
Defines prior authorization, coverage criteria, dosing limits, and prescribing requirements for Coagadex (plasma‑derived Factor X) for hereditary Factor X deficiency under CareSource medical benefit policies, affecting providers prescribing or requesting coverage for this drug.
No material clinical or coverage changes in this revision.
Coverage Criteria for Coagadex (Factor X)
FDA-Approved Indication and Dosing
Covered when ALL of the following are met:
Approve for 1 year
Requests exceeding this will be reviewed case-by-case
Coverage for Coagadex is not recommended for circumstances that are not listed in the Recommended Authorization Criteria. Requests for indications, dosing, or use outside the explicit authorization criteria will be considered case-by-case and may be denied.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.